Instructions for Nucleo C.M.F. forte capsules blister No. 30
Composition
active ingredients: sytidine-5-disodium monophosphate (CMP disodium salt), uridine-5-trisodium triphosphate (UTP trisodium salt), uridine-5-disodium diphosphate (UDP disodium salt), uridine-5-disodium monophosphate (UMP disodium salt);
1 capsule contains cytidine-5-monophosphate disodium salt (CMF disodium salt) 5 mg, uridine-5-triphosphate trisodium salt (UTP trisodium salt), uridine-5-diphosphate disodium salt (UDF disodium salt), uridine-5-monophosphate disodium salt (UMF disodium salt) totaling 3 mg (equivalent to 1,330 mg of pure uridine);
excipients: citric acid anhydrous, sodium citrate, magnesium stearate, colloidal anhydrous silicon dioxide, mannitol (E 421).
Dosage form
Capsules.
Main physicochemical properties: capsules No. 2 with a blue cap and a gray body, containing a white hygroscopic powder.
Pharmacotherapeutic group
Drugs that affect the nervous system.
ATX code N07X X.
Pharmacological properties
Pharmacodynamics
Nucleo C.M.F. Forte contains nucleotides: cytidine monophosphate (CMP), uridine triphosphate (UTP), which are widely used to treat diseases of the central nervous system (CNS).
From a biochemical point of view, the action of these components is as follows:
CMP is involved in the synthesis of a complex of lipids that form the neuronal membrane, mainly sphingomyelin - the main component of the myelin sheath. CMP is also a precursor of nucleic acids (DNA and RNA), which, in turn, are the main elements of cellular metabolism (for example, in protein synthesis).
UTP acts as a coenzyme in the synthesis of glycolipids, neuronal structures, and the myelin sheath, complementing the action of CMP. In addition, UTP acts as a source of energy in the process of muscle contraction.
CMF and UTF participate in the synthesis of phospholipids and glycolipids, which mainly make up the myelin sheath and other nerve structures. This contributes to intensive metabolic activity, which, in turn, contributes to the process of myelin sheath regeneration, regulating demyelination in peripheral nerve injuries. Thus, the combination of CMF and UTF action contributes to the regeneration of the myelin sheath, the correct conduction of nerve excitation and the restoration of muscle trophism.
Pharmacokinetics
Nucleo C.M.F. Forte contains physiological products present in the body's biological fluids, which makes its study more difficult. And this is the reason why, due to the high radiological load, studies were conducted only on experimental animals using a radioactively labeled product.
The aim of the study was to observe the absorption and pharmacokinetics of UMF, CMF, and UTF.
As a result of the study, the same metabolic pathway was identified for UMF and UTP, i.e., rapid conversion via uracil into at least one other polar radioactive fraction was detected.
The CMF compound was rapidly converted to cytosine, uracil, and at least one other polar radioactive moiety. Cytosine was then primarily converted to uracil. These results indicate that uracil is metabolized longest in the blood in the presence of cytosine, which has been formed since the beginning of CMF administration.
Indication
Treatment of neuropathies of osteoarticular origin (sciatica, radiculitis), metabolic (alcoholic, diabetic polyneuropathy), infectious origin (shingles).
Facial neuralgia, trigeminal neuralgia, intercostal neuralgia, lumbago.
Contraindication
Hypersensitivity to the components of the drug.
Interaction with other medicinal products and other types of interactions
Not installed.
Application features
Taking Nucleo C.M.F. Forte is not related to food intake. Therefore, the drug can be taken before, during or after meals.
Nucleo C.M.F. Forte contains mannitol, which may have a mild laxative effect. In the presence of stomach disorders, it is recommended to take Nucleo C.M.F. Forte with food.
Use during pregnancy or breastfeeding
The safety of the drug Nucleo C.M.F. Forte during pregnancy and breastfeeding has not been established.
The use of the drug during pregnancy or breastfeeding is possible if, in the opinion of the doctor, the expected positive effect for the woman outweighs the potential risk to the fetus/child.
Ability to influence reaction speed when driving vehicles or other mechanisms
Nucleo C.M.F. Forte does not affect the ability to drive vehicles and work with complex mechanisms.
Method of administration and doses
The drug should be taken orally, regardless of meals.
Adults: recommended dose – 1 capsule 3 times a day.
The duration of the course of treatment is determined by the doctor individually.
Children
There is insufficient data for the use of the drug in children.
Overdose
Given the low toxicity of the drug, the likelihood of poisoning is low even if the therapeutic dose is accidentally exceeded.
In case of overdose, symptomatic treatment is necessary.
Adverse reactions
Not described. However, hypersensitivity reactions are possible.
Expiration date
2 years.
Storage conditions
Store out of the reach of children at a temperature not exceeding 30 °C.
Incompatibility
Not installed.
Packaging
15 capsules in a blister, 2 blisters in a cardboard box.
Vacation category
According to the recipe.
Producer
Ferrer International, S.A.
Location of the manufacturer and its business address
Legal address
Gran Via Carlos III, 94, 08028 Barcelona, Spain.
Place of production
s/Joan Buscaya, 1-9, 08173 Sant Cugat del Bayes (Barcelona), Spain.
